Literature DB >> 16764553

Bioreactor systems for the production of biopharmaceuticals from animal cells.

James N Warnock1, Mohamed Al-Rubeai.   

Abstract

The demand for biopharmaceutical products is set to see a significant increase over the next few years. As a consequence, the processes used to produce these products must be able to meet market requirements. The present paper reviews the current technologies available for animal cell culture and highlights the advantages and disadvantages of each method, while also providing details of recent case studies. Processes are described for both suspension and anchorage-dependent cell lines.

Mesh：

Substances：

Year:  2006        PMID： 16764553     DOI： 10.1042/BA20050233

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN： 0885-4513            Impact factor:   2.431


  10 in total

1.  Cellular complexity captured in durable silica biocomposites.

Authors:  Bryan Kaehr; Jason L Townson; Robin M Kalinich; Yasmine H Awad; B S Swartzentruber; Darren R Dunphy; C Jeffrey Brinker
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

2.  Disposable polymeric cryogel bioreactor matrix for therapeutic protein production.

Authors:  Era Jain; Ashok Kumar
Journal:  Nat Protoc       Date:  2013-04-04       Impact factor: 13.491

Review 3.  Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Bioeng Biotechnol       Date:  2019-12-20

4.  Multiphase matrix of silica, culture medium and air for 3D mammalian cell culture.

Authors:  Mika Jokinen; Karen Pittois; Suzanne van den Akker; Inge Gutschoven; Tatu Assmuth; Tapio Metz; Hanna Lehtilä; Pekka Alanne
Journal:  Cytotechnology       Date:  2020-02-19       Impact factor: 2.058

5.  Continuous production process of retroviral vector for adoptive T- cell therapy.

Authors:  Sarah Inwood; Hui Xu; Mary A Black; Michael J Betenbaugh; Steven Feldman; Joseph Shiloach
Journal:  Biochem Eng J       Date:  2018-01-11       Impact factor: 3.978

6.  Direct site-specific glycoform identification and quantitative comparison of glycoprotein therapeutics: imiglucerase and velaglucerase alfa.

Authors:  Hongping Ye; John Hill; Ashley C Gucinski; Michael T Boyne; Lucinda F Buhse
Journal:  AAPS J       Date:  2014-12-13       Impact factor: 4.009

7.  Truly continuous low pH viral inactivation for biopharmaceutical process integration.

Authors:  Duarte L Martins; Jure Sencar; Nikolaus Hammerschmidt; Andreas Flicker; Johanna Kindermann; Thomas R Kreil; Alois Jungbauer
Journal:  Biotechnol Bioeng       Date:  2020-02-24       Impact factor: 4.530

8.  Production of a Foot-and-Mouth Disease Vaccine Antigen Using Suspension-Adapted BHK-21 Cells in a Bioreactor.

Authors:  Soonyong Park; Ji Yul Kim; Kyoung-Hwa Ryu; Ah-Young Kim; Jaemun Kim; Young-Joon Ko; Eun Gyo Lee
Journal:  Vaccines (Basel)       Date:  2021-05-13

9.  A Versatile Bioreactor for Dynamic Suspension Cell Culture. Application to the Culture of Cancer Cell Spheroids.

Authors:  Diana Massai; Giuseppe Isu; Denise Madeddu; Giulia Cerino; Angela Falco; Caterina Frati; Diego Gallo; Marco A Deriu; Giuseppe Falvo D'Urso Labate; Federico Quaini; Alberto Audenino; Umberto Morbiducci
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

10.  Establishing functional lentiviral vector production in a stirred bioreactor for CAR-T cell therapy.

Authors:  Qu-Lai Tang; Li-Xing Gu; Yao Xu; Xing-Hua Liao; Yong Zhou; Tong-Cun Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.